ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

Center Core Grants Picture Less Bleak; Competing Renewals To Receive 50% Of Recommended Increases

January 4, 1980

Funding Opportunities

January 17, 2003

In Brief: Alice Fordyce, Supporter of Medical Research, Dead At 86; Broder Awarded Block Lectureship

September 18, 1992

Post Reporter Responds To Criticism Of Cancer Series

January 1, 1982

Undeterred By Randomized Trial Results, AUA Calls For Baseline PSA At Age 40.

May 1, 2009

NCAB Approves CCP, Agrees To Compromise On Including Control

May 21, 1982